South Korea · Delayed Price · Currency is KRW GC Genome Statistics
Total Valuation
GC Genome has a market cap or net worth of KRW 163.19 billion. The enterprise value is 124.91 billion.
| Market Cap | 163.19B |
| Enterprise Value | 124.91B |
Important Dates
The last earnings date was Friday, April 10, 2026.
| Earnings Date | Apr 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GC Genome has 23.65 million shares outstanding. The number of shares has increased by 22.05% in one year.
| Current Share Class | 23.65M |
| Shares Outstanding | 23.65M |
| Shares Change (YoY) | +22.05% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 15.56% |
| Owned by Institutions (%) | 4.04% |
| Float | 13.04M |
Valuation Ratios
The trailing PE ratio is 30.03 and the forward PE ratio is 30.13.
| PE Ratio | 30.03 |
| Forward PE | 30.13 |
| PS Ratio | 5.00 |
| PB Ratio | 2.04 |
| P/TBV Ratio | 2.06 |
| P/FCF Ratio | 77.73 |
| P/OCF Ratio | 54.52 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 26.28, with an EV/FCF ratio of 59.50.
| EV / Earnings | 23.07 |
| EV / Sales | 3.83 |
| EV / EBITDA | 26.28 |
| EV / EBIT | 59.50 |
| EV / FCF | 59.50 |
Financial Position
The company has a current ratio of 11.82, with a Debt / Equity ratio of 0.05.
| Current Ratio | 11.82 |
| Quick Ratio | 11.20 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.90 |
| Debt / FCF | 1.80 |
| Interest Coverage | 8.46 |
Financial Efficiency
Return on equity (ROE) is 7.05% and return on invested capital (ROIC) is 3.43%.
| Return on Equity (ROE) | 7.05% |
| Return on Assets (ROA) | 1.13% |
| Return on Invested Capital (ROIC) | 3.43% |
| Return on Capital Employed (ROCE) | 1.86% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.38 |
| Inventory Turnover | 8.15 |
Taxes
In the past 12 months, GC Genome has paid 542.44 million in taxes.
| Income Tax | 542.44M |
| Effective Tax Rate | 9.11% |
Stock Price Statistics
The stock price has decreased by -14.92% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.92% |
| 50-Day Moving Average | 5,388.90 |
| 200-Day Moving Average | 6,661.13 |
| Relative Strength Index (RSI) | 71.59 |
| Average Volume (20 Days) | 127,379 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GC Genome had revenue of KRW 32.64 billion and earned 5.42 billion in profits. Earnings per share was 229.79.
| Revenue | 32.64B |
| Gross Profit | 15.22B |
| Operating Income | 1.55B |
| Pretax Income | 5.96B |
| Net Income | 5.42B |
| EBITDA | 4.20B |
| EBIT | 1.55B |
| Earnings Per Share (EPS) | 229.79 |
Balance Sheet
The company has 42.05 billion in cash and 3.77 billion in debt, with a net cash position of 38.28 billion or 1,618.47 per share.
| Cash & Cash Equivalents | 42.05B |
| Total Debt | 3.77B |
| Net Cash | 38.28B |
| Net Cash Per Share | 1,618.47 |
| Equity (Book Value) | 79.87B |
| Book Value Per Share | 3,376.93 |
| Working Capital | 49.59B |
Cash Flow
In the last 12 months, operating cash flow was 2.99 billion and capital expenditures -893.59 million, giving a free cash flow of 2.10 billion.
| Operating Cash Flow | 2.99B |
| Capital Expenditures | -893.59M |
| Depreciation & Amortization | 2.65B |
| Net Borrowing | -685.64M |
| Free Cash Flow | 2.10B |
| FCF Per Share | 88.77 |
Margins
Gross margin is 46.63%, with operating and profit margins of 4.74% and 16.59%.
| Gross Margin | 46.63% |
| Operating Margin | 4.74% |
| Pretax Margin | 18.25% |
| Profit Margin | 16.59% |
| EBITDA Margin | 12.87% |
| EBIT Margin | 4.74% |
| FCF Margin | 6.43% |
Dividends & Yields
GC Genome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.05% |
| Shareholder Yield | -22.05% |
| Earnings Yield | 3.32% |
| FCF Yield | 1.29% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GC Genome has an Altman Z-Score of 14.68 and a Piotroski F-Score of 5.
| Altman Z-Score | 14.68 |
| Piotroski F-Score | 5 |